<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391064</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2013/23</org_study_id>
    <nct_id>NCT02391064</nct_id>
  </id_info>
  <brief_title>Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS)</brief_title>
  <acronym>BICAFMS</acronym>
  <official_title>Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) - BICAFMS Study (Brief Cognitive Assessment in French MS Patients)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive disorders are common in early stage of Multiple Sclerosis (MS) and concern mainly
      information processing speed (IPS) which also influences with other cognitive functions such
      as attention, working memory and executive functions. The investigators validated a
      computerized test of IPS, the computerized speed cognitive test (CSCT), which can detect
      disorders of IPS in MS. A short battery was proposed, the brief cognitive assessment for
      multiple sclerosis (BICAMS) battery, which combines the Symbol-Digit Modalities-test (SDMT),
      a test of the IPS, and two measures of episodic memory. On the same principle, the
      investigators propose to validate a short computerized battery to improve the feasibility
      (brief computerized cognitive assessment (BCCAMS)) combining the CSCT and a computerized test
      of visual episodic memory.

      Purpose: to establish the screening value of a brief computerized cognitive assessment
      (BCCAMS) combining the computerized speed cognitive test (CSCT) and a new computerized
      episodic visual memory test (CEVMT) in French-speaking patients with multiple sclerosis as
      compared to a reference battery (MACFIMS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2015</start_date>
  <completion_date type="Actual">February 18, 2018</completion_date>
  <primary_completion_date type="Actual">February 18, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prediction by the z score BCCAMS of cognitive impairment (at least two tests MACFIMS battery &lt;1.5 SD of control subjects</measure>
    <time_frame>At the inclusion (Day 0)</time_frame>
    <description>average z scores of CEVMT and CSCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine values of neuropsychological tests in healthy according to age subjects, gender and the level education</measure>
    <time_frame>At the inclusion (Day 0) and at 1 and 6 months after the inclusion (Day 0)</time_frame>
    <description>BCCAMS and MACFIMS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability of the CEVMT to detect episodic memory deficiencies in patients with multiple sclerosis, as compared to established tests of episodic memory</measure>
    <time_frame>At the inclusion (Day 0) and at 1 and 6 months after the inclusion (Day 0)</time_frame>
    <description>California verbal learning test-II and brief-visual memory test-revised</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between alternate forms of the CEVMT and the Brief visual memory test-revised (BVMT-R)</measure>
    <time_frame>At the inclusion (Day 0) and at 1 and 6 months after the inclusion (Day 0)</time_frame>
    <description>congnitive test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction between cognitive impairment and occupational status/leisure activities</measure>
    <time_frame>At the inclusion (Day 0) and 6 months after the inclusion (Day 0)</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of possible confounders on results of cognitive testing, including depression, mood, anxiety and fatigue</measure>
    <time_frame>At the inclusion (Day 0) and at 1 and 6 months after the inclusion (Day 0)</time_frame>
    <description>scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproducibility of CSCT, CEVMT and the symbol-digit modalities test in clinical settings in patients with multiple sclerosis</measure>
    <time_frame>At 1 and 6 months after the inclusion (Day 0)</time_frame>
    <description>congnitive test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">421</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MS Relapsing-remitting under interferon beta-1b treatment in inclusion, Secondary progressive and Primary progressive MS forms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>healthy subject</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive evaluation</intervention_name>
    <description>Questionnaires for assessment of confounding factors
Cognitive evaluation
Walking tests and 9 Hole Peg Test</description>
    <arm_group_label>Patient</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Expanded Disability Status Scale (EDSS) score</intervention_name>
    <description>- EDSS score</description>
    <arm_group_label>Patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients :

          -  Aged 18-64 years

          -  Francophone

          -  MS Relapsing-remitting under interferon beta-1b treatment in inclusion, Secondary
             progressive and Primary progressive MS forms

          -  Having signed an informed consent (later than the day of inclusion and before any
             examination required by research)

          -  Being affiliated to health insurance

        Controls:

          -  Aged 18-64 years

          -  Francophone

          -  Having signed an informed consent (later than the day of inclusion and before any
             examination required by research)

          -  Being affiliated to health insurance

        Exclusion Criteria:

        Patients:

          -  Other neurological diseases with impact on cognitive functions.

          -  Severe psychiatric disease or severe depression.

          -  Current Dependence on alcohol or drugs.

          -  Modification or stop of psychotropic treatment in less than a month.

          -  Modification of MS treatment in less than a month.

          -  Visual, visual-motor and / or motor impairments excluding the ability to perform
             cognitive tests.

          -  Pregnant

        Controls:

          -  Neurologic disease and known chronic systemic with impact on cognitive functions.

          -  Severe psychiatric disease or severe depression.

          -  Current Dependence on alcohol or drugs.

          -  Psychotropic treatment

          -  Cognitive complaint

          -  Prior cognitive testing with the same tests less than one year.

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H么pital du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <zip>59385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H么pital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H么pital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H么pital de Poissy Saint Germain</name>
      <address>
        <city>Poissy</city>
        <zip>78303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognition</keyword>
  <keyword>brief computerized cognitive assessment</keyword>
  <keyword>impairment prediction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

